On September 7, 2023, it was reported that Profund Advisors LLC had acquired a new position in shares of biotechnology company Atara Biotherapeutics, Inc. (NASDAQ:ATRA) during the first quarter. According to their disclosure with the Securities and Exchange Commission (SEC), the institutional investor purchased 104,484 shares of the company’s stock, valued at approximately $303,000. As of their most recent SEC filing, Profund Advisors LLC owned around 0.11% of Atara Biotherapeutics.
In terms of financial performance, Atara Biotherapeutics released its earnings results on August 8th. The company reported a loss per share (EPS) of ($0.68) for the quarter, which fell short of the consensus estimate of ($0.65) by ($0.03). Additionally, Atara Biotherapeutics had a negative return on equity of 315.45% and a negative net margin of 4,437.45%. The company generated revenue amounting to $0.96 million for the quarter, compared to analyst estimates predicting $3.36 million in revenue.
The news also highlighted that CEO Pascal Touchon sold 30,766 shares of the company’s stock on August 16th in a transaction valued at $50,763.90 or an average price per share of $1.65. Following this sale, Touchon now directly owns 675,905 shares worth $1,115,243.25 in total. This transaction was disclosed in a filing with the SEC and can be accessed via their website.
Throughout the past three months leading up to this reportage date, insiders have sold a total of 61,915 shares of Atara Biotherapeutics’ stock with an estimated value worth $102,303. Currently, insiders hold approximately 4.50% ownership stake in the company.
While this information provides insight into the recent activities surrounding Atara Biotherapeutics and its shareholders, it should be noted that past performance does not guarantee future results. As analysts predict a projected EPS of -2.6 for the current year, it will be crucial to monitor how the company navigates any potential challenges and capitalizes on opportunities in the evolving biotechnology industry.
Bright Horizons Family Solutions Inc.
BFAM
Strong Buy
Updated on: 03/12/2023
Financial Health
Very Healthy
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Neutral
Hedge Funds and Institutions Increase Holdings in Atara Biotherapeutics as Market Performance Fluctuates
As of the latest reported data on September 7, 2023, it has been noted that there have been significant changes in the holdings of Atara Biotherapeutics by various institutional investors. Among them, ExodusPoint Capital Management LP stands out with a remarkable increase of 346.5% in its position during the first quarter. The company now owns an additional 212,229 shares, bringing its total stake to 273,484 shares worth approximately $793,000.
Another noteworthy institution is American Century Companies Inc., which has grown its holdings in Atara Biotherapeutics by 50.1% during the same period. They acquired an additional 7,553 shares, increasing their total ownership to 22,618 shares valued at around $63,000.
Envestnet Asset Management Inc. also saw a substantial increase in its position by 122.5% in the first quarter. With an additional accumulation of 17,521 shares, they now own a total of 31,827 shares worth approximately $92,000.
Rhumbline Advisers displayed a modest growth by adding an extra 4,315 shares to their existing holdings during the first quarter. Their current ownership stands at 147,372 shares valued at approximately $427,000.
Lastly, E Fund Management Co. Ltd., exhibited a slight growth compared to others with a stake increase of 21.7% during the first quarter. Acquiring an additional 5,710 shares , they now own a total of 32,062 shares worth around $93,000.
In summary it can be observed that hedge funds and other institutional investors collectively possess a substantial majority (88.79%) of Atara Biotherapeutics’ stock.
Moving on to market performance updates for Atara Biotherapeutics (NASDAQ:ATRA), it opened at $1.57 on Thursday and currently holds a market capitalization of $158.73 million. The price-to-earnings ratio stands at -0.53 with a beta of 1.03, indicating moderate volatility.
When considering the company’s performance over a 52-week period, it is observed that the stock reached a high of $5.64 and faced its lowest point at $1.25.
Technical analysis reveals that Atara Biotherapeutics has displayed a fifty-day simple moving average of $1.83 and two-hundred day simple moving average of $2.35, indicating fluctuating trends in recent months.
Research firms have also weighed in on Atara Biotherapeutics, with HC Wainwright reiterating their “buy” rating and raising its target price from $27.00 to $28.00 in a report on June 14th. However, StockNews.com gave a “sell” rating on August 17th.
It is important to note that these statistics reflect the most recent information available and may be subject to change as new developments arise in the market or additional research reports are released.
Investors and stakeholders interested in Atara Biotherapeutics can find comprehensive stock reports for further insight into the company’s operations and outlook.
Discussion about this post